New and Emerging Treatments for Rosacea.
American journal of clinical dermatology
Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.
Medical Subject Headings
Administration, Topical; Brimonidine Tartrate; Clinical Trials, Phase III as Topic; Dermatologic Agents; Dicarboxylic Acids; Drug Approval; Female; Follow-Up Studies; Forecasting; Humans; Ivermectin; Male; Oxymetazoline; Patient Satisfaction; Rosacea; Severity of Illness Index; Treatment Outcome; United States; United States Food and Drug Administration